Inclusion Criteria:

          1. Subjects must have proven pediatric cancer with confirmation at diagnosis or at the
             time of recurrence/progression and clinical determination of disease for which there
             is no known effective curative therapy or disease that is refractory to established
             proven therapies fitting into one of the following categories:

               -  Neuroblastoma- Patients that have relapsed following standard of care therapy
                  (such as high risk patients, patient presenting after age 15 months or MYCN
                  amplified, and only following (for eligible patients) high-dose chemotherapy
                  followed by hematopoietic stem cell transplantation and maintenance therapy with
                  retinoic acid and antibody therapy) or having progressed during standard of care
                  therapy and non-responsive/progressive to accepted curative chemotherapy.

               -  Brain Tumors

               -  Medulloblastomas (At relapse after standard of care therapy [surgery,
                  chemotherapy and/or radiation] and/or non-responsive/progressive on accepted
                  curative therapy)

               -  Gliomas (At relapse after standard of care therapy [surgery and/or radiation
                  and/or chemotherapy] and/or non-responsive/progressive on accepted curative
                  therapy)

               -  Ependymomas (At relapse after standard of care therapy [surgery with or without
                  radiation] and/or non-responsive/progressive on accepted curative therapy)

               -  Choroid plexus tumors (At relapse after standard of care therapy [surgery] and/or
                  non-responsive/progressive on accepted curative therapy)

               -  Craniopharyngiomas (At relapse after standard of care therapy [surgery or
                  suppressive therapy] and/or non-responsive/progressive on accepted curative
                  therapy)

               -  Dysembryoplastic neuroepithelial tumors (DNETs) (At relapse after standard of
                  care therapy [surgery] and/or non-responsive/progressive on accepted curative
                  therapy)

               -  Meningiomas (At relapse after standard of care therapy [surgery] and/or
                  non-responsive/progressive on accepted curative therapy)

               -  Primitive Neuroectodermal Tumors (PNETs) (At relapse after standard of care
                  therapy [surgery, chemotherapy, and/or radiation] and/or
                  non-responsive/progressive on accepted curative therapy)

               -  Germ cell tumors (At relapse after standard of care therapy [surgery, and/or
                  radiation and/or chemotherapy] and/or non-responsive/progressive on accepted
                  curative therapy)

               -  Rare Tumors:

               -  Soft tissue sarcoma Rhabdomyosarcoma (At relapse after standard of care therapy
                  [surgery, and/or radiation, chemotherapy] and/or non-responsive/progressive to
                  accepted curative chemotherapy) Non-rhabdomyosarcoma (At relapse after standard
                  of care therapy [surgery, and/or radiation, chemotherapy] and/or
                  non-responsive/progressive to accepted curative chemotherapy)

               -  Bone Ewings sarcoma (At relapse after standard of care therapy [surgery, and/or
                  radiation, chemotherapy] and/or non- responsive/progressive to accepted curative
                  chemotherapy) Osteosarcoma (At relapse after standard of care therapy [surgery,
                  chemotherapy] and/or non- responsive/progressive to accepted curative
                  chemotherapy)

               -  Renal Wilms tumor (At relapse after standard of care therapy [surgery, and/or
                  radiation, chemotherapy] and/or non- responsive/progressive to accepted
                  chemotherapy) Renal cell carcinoma (At relapse after standard of care therapy
                  [surgery, chemotherapy] and/or non- responsive/progressive to accepted curative
                  chemotherapy) Malignant rhabdoid tumor (At diagnosis, as there is no known
                  curative therapy) Clear Cell Sarcoma- (At relapse after standard of care therapy
                  [radiation, chemotherapy] and/or non- responsive/progressive to accepted curative
                  chemotherapy) Germ Cell tumors (At relapse after standard of care therapy
                  [surgery, chemotherapy] and/or non-responsive/progressive to accepted curative
                  chemotherapy)

               -  Liver Tumors (At relapse after standard of care therapy [surgery, chemotherapy]
                  and/or non- responsive/progressive to accepted curative chemotherapy)

          2. Subjects must be age >12 months at enrollment

          3. Subjects must be age ≤ 21 years at initial diagnosis

          4. Subjects must have measurable disease as demonstrated by residual abnormal tissue at a
             primary or metastatic site (measurable on CT or MRI) at the time of biopsy; tumor must
             be accessible for biopsy. In addition, subjects with bone or bone marrow only disease
             expected to be >75% tumor are eligible to enroll.

          5. Current disease state must be one for which there is currently no known effective
             therapy

          6. Specimens will be obtained only in a non-significant risk manner and not solely for
             the purpose of investigational testing.

          7. Lansky or Karnofsky Score must be ≥ 50

          8. Subjects without bone marrow metastases must have an ANC > 750/μl to begin treatment.

          9. Subjects with CNS disease must have been on a stable dose of steroids for 2 weeks
             prior to their biopsy and must not have progressive hydrocephalus at enrollment.

         10. Adequate liver function must be demonstrated, defined as:

               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age AND

               -  ALT (SGPT) < 10 x upper limit of normal (ULN) for age

         11. A negative serum pregnancy test is required for female participants of child bearing
             potential (≥13 years of age or after onset of menses)

         12. Both male and female post-pubertal study subjects need to agree to use one of the more
             effective birth control methods during treatment and for six months after treatment is
             stopped. These methods include total abstinence (no sex), oral contraceptives ("the
             pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or
             medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be
             used, contraceptive foam with a condom is recommended.

         13. Informed Consent: All subjects and/or legal guardians must sign informed written
             consent. Assent, when appropriate, will be obtained according to institutional
             guidelines

        Exclusion Criteria:

          1. Subjects who have received any cytotoxic chemotherapy within the last 7 days prior to
             biopsy

          2. Subjects who have received any radiotherapy to the primary sample site within the last
             14 days (radiation may be included in treatment decision after biopsy).

          3. Subjects receiving any investigational drug concurrently.

          4. Subjects with uncontrolled serious infections or a life-threatening illness (unrelated
             to tumor)

          5. Subjects with any other medical condition, including malabsorption syndromes, mental
             illness or substance abuse, deemed by the Investigator to be likely to interfere with
             the interpretation of the results or which would interfere with a subject's ability to
             sign or the legal guardian's ability to sign the informed consent, and subject's
             ability to cooperate and participate in the study